LEGN PE Ratio & Valuation,Is LEGN Overvalued

LEGN Relative Valuation

LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEGN is overvalued; if below, it's undervalued.

Historical Valuation

Legend Biotech Corp (LEGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.92 is considered Undervalued compared with the five-year average of -55.16. The fair price of Legend Biotech Corp (LEGN) is between 463.71 to 726.60 according to relative valuation methord. Compared to the current price of 22.20 USD , Legend Biotech Corp is Undervalued By 95.21%.

Relative Value

Fair Zone

463.71-726.60

Current Price：22.20

95.21%

Undervalued

-1320.12

30.24

EV/EBITDA

Legend Biotech Corp. (LEGN) has a current EV/EBITDA of 30.24. The 5-year average EV/EBITDA is -18.40. The thresholds are as follows: Strongly Undervalued below -74.44, Undervalued between -74.44 and -46.42, Fairly Valued between 9.61 and -46.42, Overvalued between 9.61 and 37.63, and Strongly Overvalued above 37.63. The current Forward EV/EBITDA of 30.24 falls within the Overvalued range.

36.18

EV/EBIT

Legend Biotech Corp. (LEGN) has a current EV/EBIT of 36.18. The 5-year average EV/EBIT is -8.31. The thresholds are as follows: Strongly Undervalued below -113.44, Undervalued between -113.44 and -60.88, Fairly Valued between 44.26 and -60.88, Overvalued between 44.26 and 96.82, and Strongly Overvalued above 96.82. The current Forward EV/EBIT of 36.18 falls within the Historic Trend Line -Fairly Valued range.

2.92

Legend Biotech Corp. (LEGN) has a current PS of 2.92. The 5-year average PS is 28.43. The thresholds are as follows: Strongly Undervalued below -14.87, Undervalued between -14.87 and 6.78, Fairly Valued between 50.07 and 6.78, Overvalued between 50.07 and 71.72, and Strongly Overvalued above 71.72. The current Forward PS of 2.92 falls within the Undervalued range.

92.74

P/OCF

Legend Biotech Corp. (LEGN) has a current P/OCF of 92.74. The 5-year average P/OCF is -25.36. The thresholds are as follows: Strongly Undervalued below -119.76, Undervalued between -119.76 and -72.56, Fairly Valued between 21.84 and -72.56, Overvalued between 21.84 and 69.04, and Strongly Overvalued above 69.04. The current Forward P/OCF of 92.74 falls within the Strongly Overvalued range.

20.70

P/FCF

Legend Biotech Corp. (LEGN) has a current P/FCF of 20.70. The 5-year average P/FCF is 25.89. The thresholds are as follows: Strongly Undervalued below -374.31, Undervalued between -374.31 and -174.21, Fairly Valued between 225.99 and -174.21, Overvalued between 225.99 and 426.09, and Strongly Overvalued above 426.09. The current Forward P/FCF of 20.70 falls within the Historic Trend Line -Fairly Valued range.

Legend Biotech Corp (LEGN) has a current Price-to-Book (P/B) ratio of 4.07. Compared to its 3-year average P/B ratio of 8.26 , the current P/B ratio is approximately -50.66% higher. Relative to its 5-year average P/B ratio of 10.72, the current P/B ratio is about -61.99% higher. Legend Biotech Corp (LEGN) has a Forward Free Cash Flow (FCF) yield of approximately -4.58%. Compared to its 3-year average FCF yield of -3.04%, the current FCF yield is approximately 50.78% lower. Relative to its 5-year average FCF yield of -3.60% , the current FCF yield is about 27.19% lower.

4.07

P/B

Median3y

8.26

Median5y

10.72

-4.58

FCF Yield

Median3y

-3.04

Median5y

-3.60

Competitors Valuation Multiple

The average P/S ratio for LEGN's competitors is 242.04, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 2.92, which is -98.79% above the industry average. Given its robust revenue growth of 69.99%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LEGN decreased by 31.41% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 160.21M to 272.33M.

The secondary factor is the P/E Change, contributed -20.02%to the performance.

Overall, the performance of LEGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

69.99%

160.21M → 272.33M

Revenue Growth

-81.38%

-78.23 → -14.57

Margin Expansion

-20.02%

-21.41 → -17.13

P/E Change

-31.41%

32.54 → 22.32

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Legend Biotech Corp (LEGN) currently overvalued or undervalued?

What is Legend Biotech Corp (LEGN) fair value?

LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Legend Biotech Corp (LEGN) is between 463.71 to 726.60 according to relative valuation methord.

How does LEGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Legend Biotech Corp (LEGN) as of Dec 15 2025?

As of Dec 15 2025, Legend Biotech Corp (LEGN) has a P/B ratio of 4.07. This indicates that the market values LEGN at 4.07 times its book value.

What is the current FCF Yield for Legend Biotech Corp (LEGN) as of Dec 15 2025?

As of Dec 15 2025, Legend Biotech Corp (LEGN) has a FCF Yield of -4.58%. This means that for every dollar of Legend Biotech Corp’s market capitalization, the company generates -4.58 cents in free cash flow.

What is the current Forward P/E ratio for Legend Biotech Corp (LEGN) as of Dec 15 2025?

As of Dec 15 2025, Legend Biotech Corp (LEGN) has a Forward P/E ratio of -1320.12. This means the market is willing to pay $-1320.12 for every dollar of Legend Biotech Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Legend Biotech Corp (LEGN) as of Dec 15 2025?

As of Dec 15 2025, Legend Biotech Corp (LEGN) has a Forward P/S ratio of 2.92. This means the market is valuing LEGN at $2.92 for every dollar of expected revenue over the next 12 months.

LEGN Valuation